Relationship Between the Expression of Thymidylate Synthase, Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase and Survival in Epithelial Ovarian Cancer

Overview

Journal J Huazhong Univ Sci Technolog Med Sci

Specialty General Medicine

Date 2010 Aug 18

PMID 20714877

Citations 1

Authors

Changyu Wang

Yanjie Weng

Hongyan Wang

Ying Shi

Ding Ma

Affiliations

Soon will be listed here.

Abstract

The mRNA and protein expression of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) and their relationship with prognosis were investigated. Real-time quantitative RT-PCR (Taqman) was used to detect the mRNA expression of TS, TP and DPD in formalin-fixed and paraffin-embedded 106 samples of epithelial ovarian cancer and 29 normal ovaries. A TATA box-binding protein (TBP) was used as an endogenous reference gene. A relationship between TS, TP, DPD expression and clinicopathologic features was investigated. The protein location and expression of TS, TP and DPD was examined in the same patients by an avidin-biotin-peroxidase immunohistochemistry. TS and TP mRNA expression levels were significantly higher in tumor group than in normal controls, with the average value of TS and TP mRNA being 6.14+/-0.62 and 0.59+/-0.06 in tumor tissue, and 0.71+/-0.14 and 0.16+/-0.04 in normal tissue, respectively. DPD mRNA expression levels were significantly lower in tumor group (0.11+/-0.02) than in normal controls (0.38+/-0.05). There was statistically significant difference in TS and TP mRNA expression levels among different pathological grades and clinical stages (P<0.05), but histological subtype was not significantly associated with TS and TP mRNA expression. DPD gene expression was not significantly associated with any clinicopathological parameters. Immunohistochemistry revealed that TP protein was mainly distributed in nucleus, and TS and DPD mainly in cytoplasm. The protein expression intensity of TS, TP and DPD was coincided with the mRNA expression levels. It was concluded that TS, TP mRNA and protein expression levels were significantly higher in epithelial ovarian cancer, and DPD mRNA and protein expression levels were significantly lower. The expression levels of TS and DPD were related to the patients' prognosis and survival. Combined gene expression levels of TS, TP and DPD represent a new variable to predict the clinical outcome in ovarian cancer. The association of TS, TP and DPD expression levels with survival suggests an importance of these genes for tumor occurrence and progression.

Citing Articles

Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.

Iizuka K, Jin C, Eshima K, Hong M, Eshima K, Fukushima M Drug Des Devel Ther. 2018; 12:673-683.

PMID: 29636601 PMC: 5881279. DOI: 10.2147/DDDT.S156635.

References

Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H . Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci. 2003; 94(7):633-8. PMC: 11160140. DOI: 10.1111/j.1349-7006.2003.tb01495.x. View

Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H . Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol. 2001; 158(2):419-29. PMC: 1850313. DOI: 10.1016/S0002-9440(10)63985-5. View

Allegra C, Parr A, Wold L, Mahoney M, Sargent D, Johnston P . Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol. 2002; 20(7):1735-43. DOI: 10.1200/JCO.2002.07.080. View

Hata K, Kamikawa T, Arao S, Tashiro H, Katabuchi H, Okamura H . Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br J Cancer. 1999; 79(11-12):1848-54. PMC: 2362806. DOI: 10.1038/sj.bjc.6690294. View

Jakobsen A, Nielsen J, Gyldenkerne N, Lindeberg J . Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol. 2005; 23(7):1365-9. DOI: 10.1200/JCO.2005.06.219. View

Soong R, Shah N, Salto-Tellez M, Tai B, Soo R, Han H . Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2008; 19(5):915-9. PMC: 2931808. DOI: 10.1093/annonc/mdm599. View

Salonga D, Danenberg K, Johnson M, Metzger R, Groshen S, Tsao-Wei D . Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000; 6(4):1322-7. View

Koopman M, Venderbosch S, van Tinteren H, Ligtenberg M, Nagtegaal I, van Krieken J . Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer. 2009; 45(11):1999-2006. DOI: 10.1016/j.ejca.2009.04.017. View

Tateishi Y, Tatemoto Y, Ohno S, Morishita K, Ueta E, Yamamoto T . Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy. Cancer Lett. 2008; 274(2):187-93. DOI: 10.1016/j.canlet.2008.09.010. View

10.

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

11.

Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D . Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol. 2003; 21(3):406-12. DOI: 10.1200/JCO.2003.06.060. View

12.

Canellakis E . Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation. J Biol Chem. 1956; 221(1):315-22. View

13.

DiSaia P, Bloss J . Treatment of ovarian cancer: new strategies. Gynecol Oncol. 2003; 90(2 Pt 2):S24-32. DOI: 10.1016/s0090-8258(03)00341-x. View

14.

Jensen S, Vainer B, Sorensen J . The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer. 2006; 120(3):694-701. DOI: 10.1002/ijc.22318. View

15.

Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N . Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer. 2001; 92(3):510-8. DOI: 10.1002/1097-0142(20010801)92:3<510::aid-cncr1349>3.0.co;2-0. View

16.

Shao S, Liu X . [Analysis of prognostic factors of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2010; 45(2):132-6. View

17.

Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K . Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res. 2005; 11(8):3025-31. DOI: 10.1158/1078-0432.CCR-04-1605. View

18.

FINK R, Fink K, HENDERSON R . beta-amino acid formation by tissue slices incubated with pyrimidines. J Biol Chem. 1953; 201(1):349-55. View

19.

Iltzsch M, el Kouni M, Cha S . Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry. 1985; 24(24):6799-807. DOI: 10.1021/bi00345a011. View

20.

Miszczak-Zaborska E, Wojcik-Krowiranda K, Kubiak R, Bienkiewicz A, Bartkowiak J . The activity of thymidine phosphorylase as a new ovarian tumor marker. Gynecol Oncol. 2004; 94(1):86-92. DOI: 10.1016/j.ygyno.2004.04.011. View